Company news

TrivarX Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Appendix 4D & Half-Year Financial Report to 31 December 2023

February 28, 2024

Response to ASX Price Query

February 22, 2024

TrivarX Receives $888k R&D Tax Incentive

February 7, 2024

TRI-001 Algorithm and Phase 2 Trial Update

February 4, 2024

December 2023 Quarterly Activities Report and Appendix 4C

January 31, 2024

Phase 2 SAMDE Study Update

November 19, 2023

Board and Management Transition

October 5, 2023

Letter to Shareholders & Notice of GM & Proxy Form

September 6, 2023

Phase 2 Trial Commences for SAMDE Study

September 3, 2023

Proposed issue of securities - MEB

August 7, 2023

Medibio Receives Firm Commitments to Raise $2.25m

August 7, 2023

June 2023 Quarterly Activities Report and Appendix 4C

July 30, 2023

Phase 1 Trial Completed for SAMDE Study

July 23, 2023

Medibio Completes Share Purchase Plan

May 29, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 26, 2023

MEB Executes Bridging Loans with Directors

April 21, 2023

Share Purchase Plan Supplementary Prospectus

April 14, 2023

Share Purchase Plan Prospectus

March 1, 2023

Half Yearly Report and Accounts

February 24, 2023

MEB to Raise up to $2.75 million By Way of a Placement & SPP

February 14, 2023

Medibio Quarterly Update and Cashflow Report

January 30, 2023

Medibio Receives R&D Tax Incentive Refund

November 14, 2022

Medibio Appoints CEO

September 19, 2022

Appendix 4E and Preliminary Final Report

August 31, 2022

Sleep Analysis Depressive Burden Study Clinical Trial

July 20, 2022

MEB to Raise $1.4m by way of a Placement & MD/CEO Resigns

June 22, 2022

Reinstatement to Quotation

June 22, 2022

Voluntary Suspension

June 16, 2022

FDA Confirm Diagnostic Method on Depression Validation Trial

May 18, 2022

Medibio Announces Entitlement Offer Result

March 10, 2022

Termination of Underwriting Agreement

March 1, 2022

Non-Renounceable Entitlement Offer Underwriting Update

January 20, 2022

MEB to Raise up to $5.7 million by way of a Placement & NREO

December 14, 2021

FDA Strategy and Regulatory Update

October 25, 2021

Appendix 4E and Annual Report

August 31, 2021

MEB Appoints R&CPMK As Communications Agency in the US

June 24, 2021

Medibio strengthens its IP protection

May 3, 2021

Re-submission of FDA 510(k) application

April 28, 2021

Consumer Mental Health App Development - Second Test Phase

April 21, 2021

MEB Share Purchase Plan Closes Strongly Oversubscribed

March 31, 2021

Supplementary Prospectus

March 31, 2021

MEB Begins Implementation of ilumen In the United Kingdom

March 18, 2021

Underwritten Share Purchase Plan Update

February 15, 2021

MEB to Raise up to $3.5m By Way of a Placement and SPP

February 10, 2021

Medibio Granted CE Mark Approval for MEBsleep

January 18, 2021

Consumer Mental Health App Initial testing phase commenced

January 10, 2021

US FDA advises further data needed for MEBsleep approval

December 28, 2020

Update on Breakthrough Device Program

December 3, 2020

Global Master License & Services Agreement with Compass

November 22, 2020

AGM Presentation

November 12, 2020

← Newer news releases · Older news releases →

Decks